Trump Slaps 100% Tariff on Patented Drugs — Why Indian Generic Makers Could Be the Biggest Winners

Trump Slaps 100% Tariff on Patented Drugs — Why Indian Generic Makers Could Be the Biggest Winners

The headlines sound alarming: the US has imposed a 100% tariff on patented pharmaceutical imports. Multiple outlets — from NDTV Profit to BusinessLine — are covering the fallout. But buried in the noise is a crucial distinction that most retail investors are missing: this tariff targets patented drugs, not generics. And India's pharmaceutical export machine runs overwhelmingly on generics.

India accounts for roughly 47% of all generic drug demand in the United States, per industry data cited in Sigachi Industries' FY25 annual report. The country has 752 US FDA-approved manufacturing facilities and produces around 60,000 generic brands across 60 therapeutic categories. When patented drugs get more expensive for American hospitals and pharmacies, the economic logic to switch to off-patent alternatives gets stronger — and Indian companies are the ones making those alternatives.

Here are five NSE-listed pharma companies whose filings show they are best positioned to ride this tailwind.

1. Sun Pharmaceutical Industries (SUNPHARMA) — The US Generics Giant

Sun Pharma is India's largest pharma company by market cap (~₹1.79 lakh crore) and already generates roughly 30% of its total sales from US formulations. Per their Q3 FY25 quarterly results, US formulation sales stood at USD 474 million for the quarter, with nine-month sales of USD 1,457 million — a 5.7% year-on-year increase. In Q2 FY25, US sales hit USD 517 million, growing 20.3% YoY. Sun's specialty portfolio (particularly in dermatology) sits alongside a deep generics pipeline, making it a dual beneficiary: its generics get a demand tailwind, and its specialty products are largely manufactured domestically for the US market.

2. Dr. Reddy's Laboratories (DRREDDY) — North America Powerhouse

Dr. Reddy's has been on a strong growth trajectory in North America. Per their Q2 FY25 quarterly results, the global generics segment posted revenues of ₹71.6 billion with 17% YoY growth, driven substantially by North America volumes and new product launches. H1 FY25 consolidated revenues hit ₹156.9 billion, up 15% year-on-year. The company's strategy of targeting complex generics — injectables, biosimilars, and limited-competition products — means it competes in higher-margin niches where the price gap between patented and generic drugs is largest. That gap just got wider.

3. Cipla Limited (CIPLA) — Fastest-Growing US Generic Player

Cipla reported an all-time high North America annual revenue of USD 906 million in FY24, representing 24% year-on-year growth, per their FY24 annual report. North America now contributes 29% of Cipla's total revenue. Their respiratory portfolio — including generic versions of blockbuster inhalers — holds significant market share in the US. Per their FY25 annual report, Cipla is among the top 15 generic players in the US by prescription volume. The respiratory category is particularly relevant here: branded inhalers are among the most expensive patented drugs in America, and the tariff will only accelerate switching to Cipla's generic alternatives.

4. Aurobindo Pharma (AUROPHARMA) — The Volume King

Aurobindo is perhaps the most US-dependent major Indian pharma company. Per their Q3 FY23 quarterly results, US revenue accounted for 46.8% of consolidated revenues at ₹3,001 crore. The company has filed a cumulative 767 ANDAs (Abbreviated New Drug Applications) with the US FDA and received final approval for 542 of them. With 85% of revenues coming from international markets and a massive manufacturing base, Aurobindo is essentially a scale play on US generic drug demand. Any tariff-driven shift from patented to generic prescriptions directly benefits their volume-based business model.

5. Alkem Laboratories (ALKEM) — The Domestic-First Hedge

Alkem offers a different kind of safety. Per their FY25 annual report, the domestic business contributes 70.2% of revenue at ₹89,837 million, while the US business is 19.4% at ₹24,818 million. While Alkem's US segment declined 10.4% YoY in FY25, the company's dominant domestic franchise (it has led the anti-infective segment for over 15 years) provides a floor. Alkem is actively expanding into chronic therapies — Neuro/CNS, Diabetes, and Dermatology. For investors seeking pharma exposure with less US-tariff volatility, Alkem's domestic-heavy mix is a natural hedge.

The Risk: API Dependence on China

One risk worth watching: India still depends significantly on China for active pharmaceutical ingredients (APIs) and key starting materials. Sigachi's FY25 annual report notes that the PLI (Production-Linked Incentive) scheme has begun reducing this dependence — from roughly 70% to lower levels — with 35 high-import-dependence APIs now being manufactured domestically. But if trade tensions spread to API supply chains, Indian manufacturers could face input cost pressure even as demand for their finished products rises.

What Retail Investors Should Do

The 100% tariff on patented drugs is not a blanket tax on all pharma imports — and Indian generics companies are not the target. If anything, they stand to gain as the cost calculus shifts further in favour of off-patent alternatives. Focus on companies with deep US generic pipelines (Sun Pharma, Dr. Reddy's, Cipla), high US revenue share (Aurobindo), or domestic-heavy portfolios that provide downside protection (Alkem). Watch for API cost inflation as a secondary risk. And remember: the 752 FDA-approved facilities in India cannot be replaced overnight — that regulatory moat is real.

Data sourced from company filings on NSE via Xaro.